Verseon Corporation

Additional Listing & Total Voting Rights

RNS Number : 3082D
Verseon Corporation
25 June 2019
 

                                                                                                                                                                       June 25, 2019

 

Verseon Corporation

 

("Verseon" or the "Company")

Additional Listing & Total Voting Rights

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 158,042 common shares of par value $0.001 each ("Common Shares") to be admitted to trading on AIM pursuant to option exercise of 5,542 common shares as well as regularly scheduled vesting of restricted stock units and restricted stock awards of 152,500 common shares (the "Issuance").

The 158,042 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on June 28, 2019 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 159,729,429 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 159,686,512. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.  

-Ends-

For further information please contact:

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000

 

 

Arden Partners (NOMAD and Joint Broker)

 

Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance) /

Fraser Marshall (Equity Sales)

+44 (0) 20 7614 5900

 

 

Cantor Fitzgerald Europe (Joint Broker)

 

Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)

Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts

Simon Vane Percy

+44 (0) 1737 821 89

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEALKSAEENEEF